Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 5/20 | 0.32 |
| ▸ | DPP4 | P27487 | 3/20 | 0.31 |
| ▸ | FAP | Q12884 | 2/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | GLP1R | P43220 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140592 | 1.00 | PRKCA (0.40) | PRKCAMMP12NR1I2ACKR3CSNK2A1 | |
| SCHEMBL4145902 | 0.94 | PRKCA (0.40) | PRKCAMMP12NR1I2ACKR3CSNK2A1 | |
| SCHEMBL4145900 | 0.94 | PRKCA (0.40) | PRKCAMMP12NR1I2ACKR3CSNK2A1 | |
| SCHEMBL4162139 | 0.92 | PRKCA (0.35) | PRKCAMMP12NR1I2CCR3DRD2 | |
| SCHEMBL4162144 | 0.92 | PRKCA (0.35) | PRKCAMMP12NR1I2CCR3DRD2 | |
| SCHEMBL4152405 | 0.92 | PRKCA (0.40) | PRKCAMMP12CSNK2A1 | |
| SCHEMBL4152401 | 0.92 | PRKCA (0.40) | PRKCAMMP12CSNK2A1 | |
| SCHEMBL4152229 | 0.92 | PRKCA (0.40) | PRKCAMMP12CSNK2A1GLP1RHTR2C | |
| SCHEMBL4152231 | 0.92 | PRKCA (0.40) | PRKCAMMP12CSNK2A1GLP1RHTR2C | |
| SCHEMBL4150441 | 0.91 | CCR3 (0.34) | PRKCAMMP12NR1I2CCR3DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-05-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | IDO1, IDO2, ZC3HAV1 | PRKCA 4320/4885MMP12 3563/4885NR1I2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.